Spots Global Cancer Trial Database for Four Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Four Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects
Official Title: A Single-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 3 Times Per Week for 4 Weeks for the Treatment of Common Warts in Pediatric Subjects
Study ID: NCT00116675
Conditions
Interventions
Study Description
Brief Summary: The primary purpose of this study is to evaluate the effectiveness in pediatric subjects of three different strengths of resiquimod gel applied to common wart(s) three times a week for four weeks. A second purpose is to evaluate the safety of the drug.
Detailed Description:
Eligibility
Minimum Age: 3 Years
Eligible Ages: CHILD
Sex: ALL
Healthy Volunteers: No
Locations
Children's Clinic of Jonesboro, PA, Jonesboro, Arkansas, United States
University of California - San Francisco, San Francisco, California, United States
Longmont Clinic/Longmont Medical Research Network, Longmont, Colorado, United States
Mercy Health Research, St. Louis, Missouri, United States
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
Rhode Island Hospital - Jane Brown Building, Providence, Rhode Island, United States
DermResearch, Inc., Austin, Texas, United States
Alpine Pediatrics, Pleasant Grove, Utah, United States
Walla Walla Clinic, Walla Walla, Washington, United States
Advanced Healthcare, Milwaukee, Wisconsin, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
